Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, +1 more
New England Journal of Medicine (2023) · n=17604
In 17,604 patients with established cardiovascular disease and overweight/obesity but no diabetes, weekly semaglutide 2.4 mg reduced the composite primary cardiovascular endpoint by 20% over a mean 40-month follow-up — the trial that took semaglutide from a metabolic drug to a cardiovascular intervention.
The SELECT trial is the cardiovascular-outcomes study that reframed how the GLP-1 receptor class is read in clinical context. Investigators randomized 17,604 patients aged 45 or older with preexisting cardiovascular disease and a BMI ≥27, but no history of diabetes, in a 1:1 ratio to once-weekly subcutaneous semaglutide 2.4 mg or placebo. The trial was event-driven; mean treatment exposure was 34.2 months and mean follow-up was 39.8 months. The primary composite cardiovascular endpoint — death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke — occurred in 569 of 8,803 patients (6.5%) on semaglutide versus 701 of 8,801 (8.0%) on placebo, a hazard ratio of 0.80 (95% CI 0.72–0.90, P<0.001). Weight loss in the semaglutide arm was substantial (~9% mean), but the cardiovascular benefit was reported with magnitude that the trial's authors and subsequent commentators have argued exceeds what weight loss alone would predict — implying direct or quasi-direct cardiovascular protective effects beyond the body-weight reduction. Adverse events leading to permanent discontinuation were higher on semaglutide (16.6% vs 8.2% on placebo), driven primarily by gastrointestinal events.
The trial population is narrow in two important ways: established cardiovascular disease at baseline (most participants had a prior MI, stroke, or symptomatic peripheral arterial disease), and absence of type 2 diabetes. Generalizability to primary prevention populations or to obese adults without prior CV events is not directly established by this trial — though the magnitude of the effect and the breadth of secondary endpoints have driven extensive use beyond the indicated population. The placebo arm received intensive lifestyle counseling alongside the placebo injection, which appropriately controls for the lifestyle component of intervention but leaves open the question of how semaglutide compares against more aggressive lipid- or hypertension-management protocols. The discontinuation rate on semaglutide is meaningful for real-world durability — adherence at scale will likely sit below the trial cohort's. Industry sponsorship by Novo Nordisk is disclosed; the trial design and primary outcome are regulatory-grade.